Reference : International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
Scientific journals : Article
Human health sciences : Hematology
http://hdl.handle.net/2268/174646
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
English
Rajkumar, Vincent []
Dimopoulos, Meletios []
Palumbo, Antonio []
Blade, Joan []
Merlini, Giampaolo []
Mateos, Maria-Victoria []
Kumar, Shaji []
Hillengass, Jens []
Kastritis, Efstathios []
Richardson, Paul []
Landgren, Ola []
Paiva, Bruno []
Dispenzieri, Angela []
Weiss, Brendan []
Leleu, Xavier []
Zweegman, Sonja []
Lonial, Sagar []
Rosinol, Laura []
Zamagni, Elena []
Jagannath, Sundar []
Sezer, Orhan []
Kristinsson, Sigurdur []
CAERS, Jo mailto [Centre Hospitalier Universitaire de Liège - CHU > > Hématologie clinique >]
Usmani, Saad []
Lahuerta, Juan José []
Johnsen, Hans Erik []
Beksac, Meral []
Cavo, Michele []
Goldschmidt, Hartmut []
Terpos, Evangelos []
Kyle, Robert []
Anderson, Kenneth []
Durie, Brian []
San Miguel, Jesus []
2014
Lancet Oncology
Elsevier
e538-548
Yes (verified by ORBi)
International
1470-2045
1474-5488
[en] This International Myeloma Working Group consensus updates the disease defi nition of multiple myeloma to include validated biomarkers in addition to existing requirements of attributable CRAB features (hypercalcaemia, renal failure, anaemia, and bone lesions). These changes are based on the identifi cation of biomarkers associated with near inevitable development of CRAB features in patients who would otherwise be regarded as having smouldering multiple myeloma. A delay in application of the label of multiple myeloma and postponement of therapy could be detrimental to these patients. In addition to this change, we clarify and update the underlying laboratory and
radiographic variables that fulfi l the criteria for the presence of myeloma-defi ning CRAB features, and the histological and monoclonal protein requirements for the disease diagnosis. Finally, we provide specifi c metrics that new biomarkers should meet for inclusion in the disease defi nition. The International Myeloma Working Group recommends the implementation of these criteria in routine practice and in future clinical trials, and recommends that future studies analyse any diff erences in outcome that might occur as a result of the new disease defi nition.
http://hdl.handle.net/2268/174646
10.1016/S1470-2045(14)70442-5

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
Lancet Oncology IMWG 2014 Diagnostic criteria.pdfPublisher postprint108.18 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.